JAK1 and acute lymphoblastic leukemia: Besides the majority of these clinical trials focusing on LSCs in AML, a few have investigated compounds targeting cells capable of initiating B-ALL or T-ALL: anti-CD25 ADC ADCT-301, bispecific anti-CD19/CD3 BiTE blinatumomab, anti-CD19 CAR-T cells, anti-CD7 CAR-T cells, JAK1/2 inhibitor ruxolitinib, Notch inhibitor BMS-906024, and CXCR4 antagonists.